Trizivir

HIV, Treatment Naive, HIV + 3 more
Treatment
3 FDA approvals
20 Active Studies for Trizivir

What is Trizivir

LamivudineThe Generic name of this drug
Treatment SummaryAZT is a medication used to treat HIV and AIDS. It works by preventing the formation of chemical bonds that are needed to complete the virus’s genetic material. AZT is effective in decreasing viral replication and improving immune system function, but it can also cause bone marrow suppression and other side effects.
Epiviris the brand name
image of different drug pills on a surface
Trizivir Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Epivir
Lamivudine
1995
178

Approved as Treatment by the FDA

Lamivudine, otherwise called Epivir, is approved by the FDA for 3 uses which include HIV and Chronic Hepatitis B Infection .
HIV
Used to treat Human Immunodeficiency Virus Type 1 (HIV-1) Infection in combination with Abacavir
Chronic Hepatitis B Infection
HIV

Effectiveness

How Trizivir Affects PatientsZidovudine is a drug that fights HIV-1 by interfering with the virus’s ability to replicate. It changes the structure of a building block of the virus’s DNA, making it unable to continue growing. This blocks the virus from multiplying and reduces its presence in the body.
How Trizivir works in the bodyZidovudine works by stopping HIV from reproducing. It does this by mimicking a natural molecule, thymidine, and then binding to the HIV's reverse transcriptase. This prevents the virus from completing its DNA chain and reproducing. Zidovudine also weakly blocks the DNA polymerase enzymes that help reproduce cellular DNA.

When to interrupt dosage

The prescribed measure of Trizivir is contingent upon the diagnosed condition, including perinatal HIV transmission, HIV Transmission and HIV. The dosage amount is also contingent upon the method of delivery (e.g. Injection, solution - Intravenous or Oral) presented in the following table.
Condition
Dosage
Administration
HIV
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
Treatment Naive
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
HIV
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
Anti-Retroviral Agents
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
Chronic Hepatitis B Infection
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
treatment failure
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

There are 20 known major drug interactions with Trizivir.
Common Trizivir Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Minor
Lamivudine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Lamivudine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Lamivudine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Allylestrenol
Minor
Lamivudine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Almasilate
Minor
Lamivudine may decrease the excretion rate of Almasilate which could result in a higher serum level.
Trizivir Toxicity & Overdose RiskOverdosing on this drug can lead to symptoms such as fatigue, headache, nausea, and vomiting. The lowest toxic dose for this drug in mice is 3084mg/kg if taken orally.

Trizivir Novel Uses: Which Conditions Have a Clinical Trial Featuring Trizivir?

122 active clinical trials are currently assessing the potential of Trizivir to reduce the risk of HIV Transmission, perinatal HIV transmission, and HIV infection.
Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
HIV
39 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4
Chronic Hepatitis B Infection
8 Actively Recruiting
Phase 3, Phase 2, Phase 1
Treatment Naive
0 Actively Recruiting
treatment failure
0 Actively Recruiting
Anti-Retroviral Agents
0 Actively Recruiting

Trizivir Reviews: What are patients saying about Trizivir?

5Patient Review
10/12/2007
Trizivir for HIV
Trizivir has been a godsend for me. After early intervention of my HIV infection, I have remained quite healthy. My T-Cells range between 400 and 850, and my viral load remains undetectable.
5Patient Review
4/23/2010
Trizivir for HIV
I've been taking this medication for a while and it's worked well for me, but my doctor is changing me to Atripla. I'm scared to change because I've been taking this a long time. I am hoping the benefits are better. This medication can cause heart disease my doctor told me, so I am changing. My first dose on Atripla was last night and felt a little weird this morning but I feel better this afternoon..
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about trizivir

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is abacavir used for?

"Abacavir is used in conjunction with other medications to treat human immunodeficiency virus (HIV) infection. Abacavir is part of a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It functions by decreasing the amount of HIV in the blood."

Answered by AI

What is Trizivir used for?

"This medication is used to treat adults who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS). It is used to replace treatment with the three active substances (abacavir, lamivudine and zidovudine) taken separately at doses similar to those in Trizivir."

Answered by AI

Can abacavir be taken alone?

"This combination of drugs is used to treat HIV infection, either on its own or with other medications."

Answered by AI

When is Triumeq generic?

"Generic versions of Triumeq may not be available until December 8, 2029, due to patent and regulatory protections."

Answered by AI

Clinical Trials for Trizivir

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Trizivir clinical trials? We made a collection of clinical trials featuring Trizivir, we think they might fit your search criteria.Go to Trials
Have you considered Trizivir clinical trials? We made a collection of clinical trials featuring Trizivir, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Trizivir clinical trials? We made a collection of clinical trials featuring Trizivir, we think they might fit your search criteria.Go to Trials